Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + NALIRIFOX
- Development stage
- Phase 2
- Lead developer
- Biotech Pharmaceutical Corp
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of nimotuzumab, a monoclonal antibody targeting EGFR, with NALIRIFOX, a chemotherapy regimen. NALIRIFOX is composed of liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil. This combination may be under investigation for treatment of pancreatic cancer.
02
Targets
Beyond the preview
Go deeper on nimotuzumab + NALIRIFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + NALIRIFOX.